A Phase 2/3 interventional study of MK-8748 and Aflibercept in Retinal Vein Occlusion and Macular Edema, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers are looking for new ways to treat macular edema after retinal vein occlusion (ME-RVO). ME-RVO happens when a vein becomes blocked in the retina, the back part of the eye. This blockage causes fluid to leak into the macula, which is the part of the retina that helps to see fine details. The buildup of fluid, called macular edema, can cause blurry vision.
In this trial, researchers want to learn if a trial medicine called MK-8748 can treat ME-RVO. A standard (usual) treatment for ME-RVO is aflibercept. However, standard treatments such as aflibercept may not work for every person.
The main goal of this trial is to learn if participants who receive MK-8748 can see as clearly as participants who receive aflibercept.
290 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
This study's planned enrollment of 1,188 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Browse Retinal Vein Occlusion studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
The main inclusion criteria include but are not limited to the following:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive MK-8748 low dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.
Drug: MK-8748
Participants receive MK-8748 high dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.
Drug: MK-8748
Participants receive aflibercept 2 mg every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.
Drug: Aflibercept
Administered via intravitreal (IVT) injection
Also known as: EYE201
Administered via IVT injection
Also known as: EYLEA
Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 24 will be assessed.
Time frame: Baseline and Week 24
Mean Change in Central Subfield Thickness (CST) from Baseline to Week 24
Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline to week 24 will be presented.
Time frame: Baseline and Week 24
Mean Change in CST from Baseline Over Time
Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Time to Absence of Diabetic Macular Edema (DME)
The absence of Diabetic Macular Edema (DME) is defined as a Central Subfield Thickness (CST) of \<300 μm measured using optical coherence tomography (OCT). The time to absence of Diabetic Macular Edema (DME) in the study eye will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid Over Time
Participants' intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal fluid over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants with Absence of Subretinal Fluid Over Time
Participants' subretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of subretinal fluid over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time
Participants' subretinal fluid and intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal and subretinal fluid over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants with Resolution of Macular Leakage on Fluorescein Angiography (FA) at Week 24
Fluorescein Angiography (FA) images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm\^2. The proportion of participants with resolution of macular leakage at Week 24 will be presented.
Time frame: Week 24
Proportion of Participants with Resolution of Macular Leakage on FA at Week 48
FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm\^2. The proportion of participants with resolution of macular leakage at Week 48 will be presented.
Time frame: Week 48
Proportion of Participants with Resolution of Macular Leakage on FA at Week 96
FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm\^2. The proportion of participants with resolution of macular leakage at Week 96 will be presented.
Time frame: Week 96
Mean Change in Vascular Leakage Area on FA in the Macula From Baseline Over Time
Vascular leakage area in the macula will be evaluated using FA images graded by a centralized reading center. The total area of macular vascular leakage will be measured in square millimeters (mm²). The mean change in vascular leakage area from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Mean Change From Baseline in Macular Ischemic Nonperfusion Area as Assessed by Optical Coherence Tomography Angiography (OCT-A)
Macular ischemic nonperfusion area (defined as areas of capillary nonperfusion or capillary drop-out within the superficial and/or deep retinal capillary plexuses) is measured in square millimeters (mm²) using OCT-A. Images are analyzed and graded by a centralized, masked independent reading center. The mean change in ischemic nonperfusion area from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants Requiring Panretinal Photocoagulation
The proportion of participants requiring panretinal photocoagulation treatment will be presented.
Time frame: Up to approximately 96 weeks
Mean Number of Intravitreal (IVT) Injections from Week 48 to Week 96
The mean number of intravitreal (IVT) Injections from week 48 to week 96 will be presented.
Time frame: Up to approximately 48 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 4 Weeks (Q4W) at Week 96
The proportion of participants on a personalized treatment interval (PTI) of Q4W at Week 96 will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 8 Weeks (Q8W) at Week 96
The proportion of participants on a personalized treatment interval (PTI) of Q8W at Week 96 will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 12 Weeks (Q12W) at Week 96
The proportion of participants on a personalized treatment interval (PTI) of Q12W at Week 96 will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 16 Weeks (Q8W) at Week 96
The proportion of participants on a personalized treatment interval (PTI) of Q16W at Week 96 will be presented.
Time frame: Up to approximately 96 weeks
Mean Change in BCVA (ETDRS letters) from Baseline Over Time
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The mean change in BCVA (ETDRS) letters from baseline over time will be presented.
Time frame: Baseline and 96 weeks
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline at Week 24
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline to year 1 will be presented.
Time frame: Baseline and week 24
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline at Week 24
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline to year 1 will be presented.
Time frame: Baseline and week 24
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline at Week 24
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline to year 1 will be presented.
Time frame: Baseline and week 24
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline Over Time
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline Over Time
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline Over Time
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline at Week 24
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline to week 24 will be presented.
Time frame: Baseline and Week 24
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline at Week 24
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline to week 24 will be presented.
Time frame: Baseline and Week 24
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline at Week 24
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline to week 24 will be presented.
Time frame: Baseline and Week 24
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline Over Time
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline Over Time
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline Over Time
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better at Week 24
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better at week 24 will be presented.
Time frame: Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better Over Time
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better at Week 24
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better at week 24 will be presented.
Time frame: Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better over time will be presented.
Time frame: Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse at Week 24
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse at week 24 will be presented.
Time frame: Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time
Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse over time will be presented.
Time frame: Up to approximately 96 weeks
Change in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Version Composite Score Over Time
The NEI-VFQ-25 is a validated and reliable 25-item survey that measures the influence of visual disability and visual symptoms on generic health domains (emotional well-being, social functioning and task-oriented domains). The composite score ranges from 0-100 with the higher score indicating better visual function. The change in NEI-VFQ-25 version composite score over time will be presented.
Time frame: Up to approximately 96 weeks
Number of Participants who Experience a Systemic Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a systemic AE will be presented.
Time frame: Up to approximately 96 weeks
Number of Participants who Experience an Ocular Adverse Event (AE)
An ocular adverse event (OAE) is defined as any untoward medical occurrence involving the eye or ocular adnexa (including eyelids, conjunctiva, lacrimal apparatus, extraocular muscles, and orbit) that: Occurs or worsens after the first administration of the investigational product (IP) or a study-related ocular procedure, and does not necessarily have a causal relationship with the IP or procedure. OAEs include, but are not limited to, changes in: Symptoms (e.g., ocular pain, photophobia, floaters, blurred vision), Visual function (e.g., best-corrected visual acuity \[BCVA\], visual field). Intraocular pressure (IOP), Anterior segment findings (e.g., conjunctival hyperemia, keratitis, anterior chamber inflammation), Posterior segment findings (e.g., vitreous inflammation, retinal hemorrhages, retinal tears or detachment, macular edema), or ocular adnexa (e.g., eyelid edema, ptosis). The number of participants who experience an ocular AE will be presented.
Time frame: Up to approximately 96 weeks
Number of Participants who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 96 weeks
Number of Participants with Antidrug Antibodies (ADA) to MK-8748
Blood samples collected at designated timepoints will be used to determine the ADA response to MK-8748. The number of participants with ADA to MK-8748 will be presented.
Time frame: At designated time points (up to approximately 96 weeks)
Maximum Plasma Concentration (Cmax) of MK-8748
Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-8748.
Time frame: At designated time points (up to approximately 96 weeks)
Plasma Trough Concentration (Ctrough) of MK-8748
Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-8748.
Time frame: At designated time points (up to approximately 96 weeks)
No study locations are listed for this record.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Start is estimated for Dec 2026; primary completion for Nov 2029, 34 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.